168 related articles for article (PubMed ID: 29136299)
1. Malignancy in Renal Transplant Recipients Exposed to Cyclophosphamide Prior to Transplantation for the Treatment of Native Glomerular Disease.
Jorgenson MR; Descourouez JL; Singh T; Astor BC; Panzer SE
Pharmacotherapy; 2018 Jan; 38(1):51-57. PubMed ID: 29136299
[TBL] [Abstract][Full Text] [Related]
2. Malignancy risk in kidney transplant recipients exposed to immunosuppression pre-transplant for the treatment of glomerulonephritis.
Massicotte-Azarniouch D; Detwiler RK; Hu Y; Falk RJ; Saha MK; Hogan SL; Derebail VK
Nephrol Dial Transplant; 2023 Aug; 38(9):2009-2018. PubMed ID: 36549661
[TBL] [Abstract][Full Text] [Related]
3. Infections Following Kidney Transplantation After Exposure to Immunosuppression for Treatment of Glomerulonephritis.
Massicotte-Azarniouch D; Detwiler RK; Hu Y; Falk RJ; Saha MK; van Duin D; Hogan SL; Derebail VK
Am J Kidney Dis; 2023 Dec; ():. PubMed ID: 38160700
[TBL] [Abstract][Full Text] [Related]
4. Prognosis of Kidney Transplant Recipients With Pretransplantation Malignancy: A Nationwide Population-Based Cohort Study in Taiwan.
Chiu HF; Chung MC; Chung CJ; Yu TM; Shu KH; Wu MJ
Transplant Proc; 2016 Apr; 48(3):918-20. PubMed ID: 27234767
[TBL] [Abstract][Full Text] [Related]
5. Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy.
van den Brand JA; van Dijk PR; Hofstra JM; Wetzels JF
Clin J Am Soc Nephrol; 2014 Jun; 9(6):1066-73. PubMed ID: 24855280
[TBL] [Abstract][Full Text] [Related]
6. Effect of immunosuppression for primary renal disease on the risk of cancer in subsequent renal transplantation: a population-based retrospective cohort study.
Hibberd AD; Trevillian PR; Wlodarczyk JH; Kemp DG; Stein AM; Gillies AH; Heer MK; Sheil AG
Transplantation; 2013 Jan; 95(1):122-7. PubMed ID: 23238532
[TBL] [Abstract][Full Text] [Related]
7. Cancer development and mortality differences in patients with glomerulonephritis after renal biopsy: a single center retrospective cohort study.
Ryu H; Kim K; Ryu J; Son HE; Ryu JY; Kim S; Na KY; Chae DW; Chin HJ;
BMC Nephrol; 2020 Jun; 21(1):221. PubMed ID: 32522167
[TBL] [Abstract][Full Text] [Related]
8. Recurrent Glomerulonephritis in Renal Transplantation: Experience in Our Renal Transplantation Center.
Cañas L; López D; Pérez JF; Bancu I; Juega J; Ariza A; Bonet J; Lauzurica R
Transplant Proc; 2015 Oct; 47(8):2354-6. PubMed ID: 26518925
[TBL] [Abstract][Full Text] [Related]
9. Cyclophosphamide exposure pretransplant is associated with complications in the first year after kidney transplant.
Sharif A; Chand S; Krishnan H; Smith S; Markarian N; Borrows R; Cockwell P
Exp Clin Transplant; 2011 Aug; 9(4):236-40. PubMed ID: 21819367
[TBL] [Abstract][Full Text] [Related]
10. Patient characteristics and outcomes by GN subtype in ESRD.
O'Shaughnessy MM; Montez-Rath ME; Lafayette RA; Winkelmayer WC
Clin J Am Soc Nephrol; 2015 Jul; 10(7):1170-8. PubMed ID: 26092830
[TBL] [Abstract][Full Text] [Related]
11. The effect of primary renal disease upon outcomes after renal transplant.
Garland S; Pullerits K; Chukwu CA; Chinnadurai R; Middleton R; Kalra PA
Clin Transplant; 2024 Mar; 38(3):e15216. PubMed ID: 38450843
[TBL] [Abstract][Full Text] [Related]
12. De novo congestive heart failure after kidney transplantation: a common condition with poor prognostic implications.
Lentine KL; Schnitzler MA; Abbott KC; Li L; Burroughs TE; Irish W; Brennan DC
Am J Kidney Dis; 2005 Oct; 46(4):720-33. PubMed ID: 16183428
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.
Mok CC; Ying KY; Ng WL; Lee KW; To CH; Lau CS; Wong RW; Au TC
Am J Med; 2006 Apr; 119(4):355.e25-33. PubMed ID: 16564783
[TBL] [Abstract][Full Text] [Related]
14. Influence of maintenance steroids on the outcomes in deceased-donor kidney transplant recipients exposed to prolonged pretransplantation dialysis.
Sureshkumar KK; Hussain SM; Thai NL; Marcus RJ
Transplant Proc; 2013; 45(1):99-101. PubMed ID: 23375281
[TBL] [Abstract][Full Text] [Related]
15. Posttransplantation glomerulonephritis: risk factors associated with kidney allograft loss.
Ostrowska J; Pazik J; Lewandowski Z; Mróz A; Perkowska-Ptasińska A; Durlik M
Transplant Proc; 2007 Nov; 39(9):2751-3. PubMed ID: 18021977
[TBL] [Abstract][Full Text] [Related]
16. Malignancy in renal transplant recipients: a single-center experience in Thailand.
Ruangkanchanasetr P; Lauhawatana B; Leawseng S; Kitpanich S; Lumpaopong A; Thirakhupt P
J Med Assoc Thai; 2012 May; 95 Suppl 5():S12-6. PubMed ID: 22934439
[TBL] [Abstract][Full Text] [Related]
17. Association of Sirolimus Use With Risk for Skin Cancer in a Mixed-Organ Cohort of Solid-Organ Transplant Recipients With a History of Cancer.
Karia PS; Azzi JR; Heher EC; Hills VM; Schmults CD
JAMA Dermatol; 2016 May; 152(5):533-40. PubMed ID: 26792250
[TBL] [Abstract][Full Text] [Related]
18. Risk of malignancy with long-term immunosuppression in renal transplant recipients.
Agraharkar ML; Cinclair RD; Kuo YF; Daller JA; Shahinian VB
Kidney Int; 2004 Jul; 66(1):383-9. PubMed ID: 15200447
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for malignancy in Japanese renal transplant recipients.
Imao T; Ichimaru N; Takahara S; Kokado Y; Okumi M; Imamura R; Namba Y; Isaka Y; Nonomura N; Okuyama A
Cancer; 2007 May; 109(10):2109-15. PubMed ID: 17407138
[TBL] [Abstract][Full Text] [Related]
20. Basiliximab: a review of its use as induction therapy in renal transplantation.
Chapman TM; Keating GM
Drugs; 2003; 63(24):2803-35. PubMed ID: 14664658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
